1310 Supporting dose decisions for antibody drug conjugates (ADC) through combined efficacy and toxicity modeling

1310 Supporting dose decisions for antibody drug conjugates (ADC) through combined efficacy and toxicity modeling

Opis bibliograficzny
Główni autorzy:	Khomveer Singh, Rahul Sing, Bhairav Paleja, Madhav Channavazzala
Format:	Artykuł
Język:	English
Wydane:	BMJ Publishing Group 2023-11-01
Seria:	Journal for ImmunoTherapy of Cancer

Podobne zapisy

1275 Optimizing lipid nano-particle (LNP) design for mRNA drug delivery, efficacy, and dose prediction using mechanistic modeling
od: Bhairav Paleja, i wsp.
Wydane: (2023-11-01)

ANTIBODY DRUG CONJUGATES (ADCS)
od: E. Terpos
Wydane: (2023-05-01)

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors
od: Xi Li, i wsp.
Wydane: (2024-04-01)

Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)
od: Iftekhar Mahmood
Wydane: (2021-10-01)

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
od: Yan Liang, i wsp.
Wydane: (2024-01-01)

Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
od: Alfonso López de Sá, i wsp.
Wydane: (2023-12-01)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
od: Blair McNamara, i wsp.
Wydane: (2023-11-01)

Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design
od: Kulkarni, Chethana, i wsp.
Wydane: (2016)

Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment
od: Xiaolan Xu, i wsp.
Wydane: (2024-04-01)

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
od: Manar Hammood, i wsp.
Wydane: (2021-07-01)

Antibody–drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)
od: Peng-Hui Wang, i wsp.
Wydane: (2024-11-01)

Nicholas Caetani. The warrior count (1310-1348)
od: Emiliano Bultrini
Wydane: (2022-12-01)

Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database
od: PingPing Long, i wsp.
Wydane: (2024-05-01)

Understanding the Toxicity Profile of Approved ADCs
od: Pablo Ballestín, i wsp.
Wydane: (2025-02-01)

13.10J Structural Mechanics, Fall 2002
od: Patrikalakis, N. M. (Nicholas M.), i wsp.
Wydane: (2002)

Legal postition of women in the medieval City of Lastovo 1310.
od: Vilma Pezelj, i wsp.
Wydane: (2013-01-01)

A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer
od: Xuwei Hong, i wsp.
Wydane: (2023-11-01)

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis
od: Umesh Kathad, i wsp.
Wydane: (2024-01-01)

Antibody–drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): Anti-HER2/neu
od: Peng-Hui Wang, i wsp.
Wydane: (2024-11-01)

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
od: Linlin Tang, i wsp.
Wydane: (2024-02-01)

A Simple Method for the Prediction of Human Concentration–Time Profiles and Pharmacokinetics of Antibody–Drug Conjugates (ADC) from Rats or Monkeys
od: Iftekhar Mahmood
Wydane: (2022-06-01)

1407 Expanding the therapeutic index of MMAE-based antibody-drug conjugates (ADCs) with a novel linker system (LD343)
od: Lei Wang, i wsp.
Wydane: (2023-11-01)

Multiscale, mechanistic model of Rheumatoid Arthritis to enable decision making in late stage drug development
od: Dinesh Bedathuru, i wsp.
Wydane: (2024-11-01)

The Stellar Content of the Young Open Cluster Berkeley 50 (IC 1310)
od: Meghan Speckert, i wsp.
Wydane: (2024-01-01)

Pravni položaj žene prema Lastovskom statutu iz 1310. g.
od: Vilma Pezelj, i wsp.
Wydane: (2013-10-01)

Pravni položaj žene prema Lastovskom statutu iz 1310. g.
od: Vilma Pezelj, i wsp.
Wydane: (2013-10-01)

Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization
od: Salaheldin Hamed, i wsp.
Wydane: (2024-03-01)

Kinetic models towards an enhanced understanding of diverse ADC conjugation reactions
od: Jan Tobias Weggen, i wsp.
Wydane: (2024-07-01)

Research Progress on Mechanisms and Optimization Methods for Toxicity Induced by Antibody–Drug Conjugates
od: Yanli JIA, i wsp.
Wydane: (2024-07-01)

1101-1310 / 1690-1892 Tarihleri Arasında Görev Yapan Rumeli Kazaskerleri
od: Cihan Kılıç
Wydane: (2023-03-01)

Degradation Characteristics and Reliability Assessment of 1310 nm VCSEL for Microwave Photonic Link
od: Wenyuan Liao, i wsp.
Wydane: (2022-05-01)

Development of pico-satellite : MEMS based ADCS sensors
od: Rahul Agrawal
Wydane: (2010)

1153 BCG022: a HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types
od: Yi Yang, i wsp.
Wydane: (2023-11-01)

Diverse Roles of Antibodies in Antibody–Drug Conjugates
od: Aiko Yamaguchi, i wsp.
Wydane: (2025-01-01)

Antibody-Drug Conjugates in Cancer
od: Marcus Vetter
Wydane: (2024-06-01)

Antibody drug conjugates in the clinic
od: Edidiong Udofa, i wsp.
Wydane: (2024-11-01)

Introduction to Antibody-Drug Conjugates
od: Mark C. Pettinato
Wydane: (2021-10-01)

Unlocking the Potential of Antibody-Drug Conjugates in Cancer Medicine: Efficacy and Side Effects
od: Marcus Vetter
Wydane: (2023-10-01)

The effect of atmosphere conditions on performance of free space optics in Malaysia at 1310nm and 1550nm /
od: Norizah Md. Ishak, 1975-, i wsp.
Wydane: (2010)

GI-POF Transmission At Different Bit Rates, Fiber Lengths and Wavelengths: 1310 and 1550 Nm
od: Hossam Selmy, i wsp.
Wydane: (2024-01-01)